Treatment of non-metastatic castration-resistant prostate cancer: focus on apalutamide.

Cancer Manag Res · 2019 · PMC6682169 · PMID 31534371

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Of note, the OS data were not mature at the time of publication but apalutamide showed a trend toward improved OS with HR of 0.70.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.